Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University identified a new class of 4-trifluoromethylquinoline derivatives that demonstrated potent anti-prostate cancer activity by inhibiting the serum/glucocorticoid-regulated kinase 1 (SGK1).